Literature DB >> 31679154

Cystic Fibrosis Diagnosis in Newborns, Children, and Adults.

Carlo Castellani1, Barry Linnane2, Iwona Pranke3, Federico Cresta1, Isabelle Sermet-Gaudelus3, Daniel Peckham4.   

Abstract

The diagnosis of cystic fibrosis (CF) has traditionally relied on the presence of clinical features of the disease. Today, diagnosis through newborn screening (NBS) is becoming the standard of modern CF care. CF NBS programs can identify CF prior to clinical presentation, but for the advantages of an early diagnosis to accrue a scrupulous system must be in place to ensure all steps in the program are performing. As we move rapidly into the era of CF transmembrane conductance regulator (CFTR) protein modulators, the opportunity to start a presymptomatic infant, identified through CF NBS, on these agents offers the prospect of true disease-modifying interventions which could result in a paradigm shift in CF care.Conversely, the introduction of NBS has resulted in many children being asymptomatic at the time of diagnosis. Some screened newborns are classified as "CF Screening Positive, Inconclusive Diagnosis", or "CFTR-related metabolic syndrome" when the diagnosis can neither be confirmed nor excluded. Appropriate assessment and follow-up should be arranged at specialist centers as a proportion of these infants and adults will eventually be diagnosed with CF.Symptoms and signs are particularly pertinent when considering a diagnosis of CF outside the context of NBS. In older patients with a late diagnosis, the spectrum of clinical presentation can be very variable with vigilant clinicians from multiple specialties suspecting the diagnosis in conditions such as recurrent pulmonary infections, male infertility, pancreatitis, nasal polyposis, and malabsorption.In addition to clinical symptoms or positive NBS results, sweat test and genetic analysis are cornerstones in the diagnosis of CF, but in some cases the diagnosis cannot be confirmed on genetic or sweat testing. Difficult diagnosis may be supported by in vivo or ex vivo electrophysiology measurements on respiratory or intestinal epithelia. This can be done by either measuring transepithelial nasal potential difference or intestinal current measurements. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31679154     DOI: 10.1055/s-0039-1697961

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  5 in total

Review 1.  Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy.

Authors:  Victor Emanuel Miranda Soares; Thiago Inácio Teixeira do Carmo; Fernanda Dos Anjos; Jonatha Wruck; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini; Débora Tavares de Resende E Silva
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

Review 2.  The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic Fibrosis.

Authors:  Anne Bergougnoux; Maureen Lopez; Emmanuelle Girodon
Journal:  Int J Neonatal Screen       Date:  2020-03-21

3.  Impact of newborn screening for cystic fibrosis on clinical outcomes of pediatric patients: 10 years' experience in Lodz Voivodship.

Authors:  M Olszowiec-Chlebna; E Mospinek; J Jerzynska
Journal:  Ital J Pediatr       Date:  2021-04-09       Impact factor: 2.638

Review 4.  National Guidelines for the Performance of the Sweat Test in Diagnosis of Cystic Fibrosis on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine and the Cystic Fibrosis Centre - Paediatrics and adults, University Hospital Centre Zagreb.

Authors:  Jasna Leniček Krleža; Merica Aralica; Duška Tješić-Drinković; Karolina Crneković; Jelena Culej; Gordana Fressl Juroš; Verica Horvat; Dara Metzner; Dijana Pamuković Jaram; Alma Pipić Kitter; Fran Smaić; Sanela Šimić Vojak; Livija Šimičević; Valentina Verić
Journal:  Biochem Med (Zagreb)       Date:  2022-02-15       Impact factor: 2.313

Review 5.  Proteomics and Metabolomics for Cystic Fibrosis Research.

Authors:  Nara Liessi; Nicoletta Pedemonte; Andrea Armirotti; Clarissa Braccia
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.